0000950170-23-041440.txt : 20230810 0000950170-23-041440.hdr.sgml : 20230810 20230810164642 ACCESSION NUMBER: 0000950170-23-041440 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230808 FILED AS OF DATE: 20230810 DATE AS OF CHANGE: 20230810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Graham G. Walmsley CENTRAL INDEX KEY: 0001777517 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 231160319 BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 1650 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 1650 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 ownership.xml 4 X0508 4 2023-08-08 0001744659 Akero Therapeutics, Inc. AKRO 0001777517 Graham G. Walmsley C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 true false false false false Common Stock 2023-08-08 4 P false 25000 42.0590 A 600000 I See Footnote Common Stock 2168 D The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $41.8634 to $42.3525, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. /s/ Jonathan Young, Attorney-in-Fact 2023-08-10